Which has higher earnings and valuation, NVCR or GKOS?

NovoCure has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.05 -$136.23M -$1.53 N/A Glaukos $507.44M 14.67 -$187.69M -$3.28 N/A

Is NVCR or GKOS more profitable?

NovoCure has a net margin of -25.66% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Glaukos -34.34% -6.92% -5.25%

Does the media favor NVCR or GKOS?

In the previous week, NovoCure had 11 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for NovoCure and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.09 beat NovoCure's score of 0.09 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NVCR or STVN?

NovoCure currently has a consensus price target of $27.29, suggesting a potential upside of 58.27%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has preferable earnings & valuation, NVCR or STVN?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.05 -$136.23M -$1.53 N/A Stevanato Group €1.34B 4.10 €158.21M €0.59 30.76

Does the media favor NVCR or STVN?

In the previous week, NovoCure had 10 more articles in the media than Stevanato Group. MarketBeat recorded 16 mentions for NovoCure and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.76 beat NovoCure's score of 0.09 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVCR or BLCO more profitable?

Bausch + Lomb has a net margin of -4.21% compared to NovoCure's net margin of -25.66%. Bausch + Lomb's return on equity of 3.60% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media favor NVCR or BLCO?

In the previous week, NovoCure had 13 more articles in the media than Bausch + Lomb. MarketBeat recorded 16 mentions for NovoCure and 3 mentions for Bausch + Lomb. NovoCure's average media sentiment score of 0.09 beat Bausch + Lomb's score of -0.10 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, NVCR or LQDA?

Liquidia has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.05 -$136.23M -$1.53 N/A Liquidia $158.32M 35.96 -$68.92M $0.14 457.21

Is NVCR or LQDA more profitable?

Liquidia has a net margin of 7.74% compared to NovoCure's net margin of -25.66%. Liquidia's return on equity of 46.82% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Liquidia 7.74% 46.82% 7.06%

Does the media refer more to NVCR or LQDA?

In the previous week, Liquidia had 2 more articles in the media than NovoCure. MarketBeat recorded 18 mentions for Liquidia and 16 mentions for NovoCure. NovoCure's average media sentiment score of 0.09 beat Liquidia's score of 0.01 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, NVCR or LIVN?

NovoCure has higher earnings, but lower revenue than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.05 -$136.23M -$1.53 N/A LivaNova $1.39B 3.05 -$242.47M $1.95 39.57

Is NVCR or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to NovoCure's net margin of -25.66%. LivaNova's return on equity of 16.48% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% LivaNova 7.48% 16.48% 7.59%

Does the media refer more to NVCR or LIVN?

In the previous week, NovoCure had 11 more articles in the media than LivaNova. MarketBeat recorded 16 mentions for NovoCure and 5 mentions for LivaNova. LivaNova's average media sentiment score of 0.43 beat NovoCure's score of 0.09 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NovoCure (NVCR) Competitors

$17.24 +0.39 (+2.31%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$17.29 +0.05 (+0.29%)

As of 06/9/2026 07:44 PM Eastern

Compare

NVCR vs. GKOS, STVN, BLCO, LQDA, and LIVN

Should you buy NovoCure stock or one of its competitors? MarketBeat compares NovoCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NovoCure include Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Liquidia (LQDA), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does NovoCure compare to Glaukos?

NovoCure (NASDAQ:NVCR) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

In the previous week, NovoCure had 11 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for NovoCure and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.09 beat NovoCure's score of 0.09 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NovoCure has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.05	-$136.23M	-$1.53	N/A
Glaukos	$507.44M	14.67	-$187.69M	-$3.28	N/A

NovoCure has a net margin of -25.66% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Glaukos	-34.34%	-6.92%	-5.25%

NovoCure has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

NovoCure presently has a consensus target price of $27.29, indicating a potential upside of 58.27%. Glaukos has a consensus target price of $146.17, indicating a potential upside of 15.35%. Given NovoCure's higher possible upside, research analysts clearly believe NovoCure is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

NovoCure and Glaukos tied by winning 8 of the 16 factors compared between the two stocks.

How does NovoCure compare to Stevanato Group?

NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

NovoCure currently has a consensus price target of $27.29, suggesting a potential upside of 58.27%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.05	-$136.23M	-$1.53	N/A
Stevanato Group	€1.34B	4.10	€158.21M	€0.59	30.76

In the previous week, NovoCure had 10 more articles in the media than Stevanato Group. MarketBeat recorded 16 mentions for NovoCure and 6 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.76 beat NovoCure's score of 0.09 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.6% of NovoCure shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Stevanato Group has a net margin of 11.76% compared to NovoCure's net margin of -25.66%. Stevanato Group's return on equity of 10.27% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Stevanato Group	11.76%	10.27%	6.08%

NovoCure has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Summary

Stevanato Group beats NovoCure on 11 of the 17 factors compared between the two stocks.

How does NovoCure compare to Bausch + Lomb?

NovoCure (NASDAQ:NVCR) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

NovoCure presently has a consensus target price of $27.29, suggesting a potential upside of 58.27%. Bausch + Lomb has a consensus target price of $17.92, suggesting a potential upside of 14.17%. Given NovoCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NovoCure is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

NovoCure has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

In the previous week, NovoCure had 13 more articles in the media than Bausch + Lomb. MarketBeat recorded 16 mentions for NovoCure and 3 mentions for Bausch + Lomb. NovoCure's average media sentiment score of 0.09 beat Bausch + Lomb's score of -0.10 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bausch + Lomb has a net margin of -4.21% compared to NovoCure's net margin of -25.66%. Bausch + Lomb's return on equity of 3.60% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Bausch + Lomb	-4.21%	3.60%	1.69%

NovoCure has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.05	-$136.23M	-$1.53	N/A
Bausch + Lomb	$5.10B	1.10	-$360M	-$0.62	N/A

Summary

NovoCure beats Bausch + Lomb on 10 of the 15 factors compared between the two stocks.

How does NovoCure compare to Liquidia?

NovoCure (NASDAQ:NVCR) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Liquidia has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.05	-$136.23M	-$1.53	N/A
Liquidia	$158.32M	35.96	-$68.92M	$0.14	457.21

Liquidia has a net margin of 7.74% compared to NovoCure's net margin of -25.66%. Liquidia's return on equity of 46.82% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Liquidia	7.74%	46.82%	7.06%

84.6% of NovoCure shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NovoCure has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

In the previous week, Liquidia had 2 more articles in the media than NovoCure. MarketBeat recorded 18 mentions for Liquidia and 16 mentions for NovoCure. NovoCure's average media sentiment score of 0.09 beat Liquidia's score of 0.01 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure presently has a consensus price target of $27.29, indicating a potential upside of 58.27%. Liquidia has a consensus price target of $55.63, indicating a potential downside of 13.10%. Given NovoCure's higher possible upside, equities analysts plainly believe NovoCure is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Summary

Liquidia beats NovoCure on 12 of the 17 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

NovoCure (NASDAQ:NVCR) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

NovoCure has higher earnings, but lower revenue than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.05	-$136.23M	-$1.53	N/A
LivaNova	$1.39B	3.05	-$242.47M	$1.95	39.57

LivaNova has a net margin of 7.48% compared to NovoCure's net margin of -25.66%. LivaNova's return on equity of 16.48% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
LivaNova	7.48%	16.48%	7.59%

NovoCure presently has a consensus target price of $27.29, suggesting a potential upside of 58.27%. LivaNova has a consensus target price of $79.38, suggesting a potential upside of 2.86%. Given NovoCure's higher possible upside, equities research analysts plainly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

NovoCure has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

In the previous week, NovoCure had 11 more articles in the media than LivaNova. MarketBeat recorded 16 mentions for NovoCure and 5 mentions for LivaNova. LivaNova's average media sentiment score of 0.43 beat NovoCure's score of 0.09 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

LivaNova beats NovoCure on 11 of the 16 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.30B	$6.65B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-11.27	18.68	24.74	23.76
Price / Sales	3.05	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	5.67	8.06	10.47	6.72
Net Income	-$136.23M	$23.83M	$3.56B	$337.35M
7 Day Performance	6.75%	-2.51%	-0.96%	-1.21%
1 Month Performance	-3.63%	2.22%	1.25%	1.41%
1 Year Performance	-6.20%	36.40%	20.49%	23.64%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	2.7592 of 5 stars	$17.24 +2.3%	$27.29 +58.3%	+2.0%	$1.95B	$655.35M	N/A	1,605
GKOS Glaukos	3.7008 of 5 stars	$103.41 +0.1%	$146.17 +41.3%	+34.0%	$6.07B	$507.44M	N/A	1,094	Positive News
STVN Stevanato Group	2.7007 of 5 stars	€18.86 -0.1%	N/A	-22.0%	€5.71B	€1.34B	31.97	6,010	Gap Up
BLCO Bausch + Lomb	2.7638 of 5 stars	$15.37 -1.8%	$18.08 +17.7%	+31.2%	$5.58B	$5.10B	N/A	13,000	Short Interest Increase
LQDA Liquidia	2.8095 of 5 stars	$58.74 -5.0%	$50.88 -13.4%	+255.2%	$5.50B	$288.07M	419.60	50	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors